Systemic administration of GMP induces anxiolytic-like behavior in rats

Pharmacology Biochemistry and Behavior

Volumn 96, Issue 3, 2010, Pages 306-311

  Almeida, Roberto Farina ^a   Cereser, Victor Hermes ^a   Faraco, Rafael Berger ^a   Böhmer, Ana Elisa ^a   Souza, Diogo Onofre ^a   Ganzella, Marcelo ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Anxiety; Anxiolytic like behavior; Cerebrospinal fluid; Diazepam; Elevated plus maze task; GMP; Guanine based purines; Light dark task; Open field

Indexed keywords

DIAZEPAM; GUANOSINE PHOSPHATE; ANXIOLYTIC AGENT; GLUTAMIC ACID; PURINE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; MALE; MAZE TEST; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; RAT; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; EXPLORATORY BEHAVIOR; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; MOTOR ACTIVITY; PHYSIOLOGY; PSYCHOLOGY; WISTAR RAT;

5'-GUANYLIC ACID; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; GLUTAMIC ACID; MALE; MOTOR ACTIVITY; PURINES; RATS; RATS, WISTAR; GUANOSINE MONOPHOSPHATE;

ANIMALIA; RATTUS; RATTUS NORVEGICUS; RODENTIA;

EID: 77954763188     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2010.05.022     Document Type: Article

References (50)

1. Baron B.M., Dudley M.W., McCarty D.R., Miller F.P., Reynolds I.J., Schmidt C.J. Guanine nucleotides are competitive inhibitors of N-Methyl-D-Aspartate at its receptor site both in vitro and in vivo. J Pharmacol Exp Ther 1989, 250:162-169.
2. Bergink V., van Megen H.J., Westenberg H.G. Glutamate and anxiety. Eur Neuropsychopharmacol 2004, 14:175-183.
3. Bourin M., Hascoët M. The mouse light/dark box test. Eur J Pharmacol 2003, 463:55-65.
4. Chojnacka-Wojcik E., Klodzinska A., Pilc A. Glutamate receptor ligands as anxiolytics. Curr Opin Investig Drugs 2001, 2:1112-1119.
5. Crawley J.N., Goodwin F.K. Preliminary report of a simple animal behaviour for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 1980, 13:167-170.
6. Cryan J.F., Kelly P.H., Neijt H.C., Sansig G., Flor P.J., van Der Putten H. Antidepressant and anxiolyticlike effects in mice lacking the group III metabotropic glutamate receptor mGluR7. Eur J Neurosci 2003, 11:2409-2417.
7. Danbolt N.C. Glutamate uptake. Prog Neurobiol 2001, 65(1):1-105. Sep 2001.
8. Frizzo M.E., Lara D.R., Prokopiuk A.S., Vargas C.R., Salbego C.G., Wajner M. Guanosine enhances glutamate uptake in brain cortical slices at normal and excitotoxic conditions. Cell Mol Neurobiol 2002, 22:353-363.
9. Frizzo M.E., Soares A.F., Dall'Onder L.P., Lara D.R., Swanson R.A., Souza D.O. Extracellular conversion of guanine-based purines to guanosine specifically enhances astrocyte glutamate uptake. Brain Res 2003, 972:84-89.
10. Hoffman E.J., Mathew S.J. Anxiety Disorders: A Comprehensive Review of Pharmacotherapies Mt Sinai. J Med 2008, 75:248-262.
11. Izquierdo I., Bevilaqua L.R., Rossato J.I., Bonini J.S., Medina J.H., Cammarota M. Different molecular cascades in different sites of the brain control memory consolidation. Trends Neurosci 2006, 29:496-505.
12. Kapus G.L., Gacsályi I., Vegh M., Kompagne H., Hegedus E., Leveleki C., et al. Antagonism of AMPA receptors produces anxiolytic-like behavior in rodents: effects of GYKI 52466 and its novel analogues. Psychopharmacology 2008, 198(2):231-241.
13. Kehne J.H., McCloskey T.C., Baron B.M., Chi E.M., Harrison B.L., Whitten J.P. NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations. Eur J Pharmacol 1991, 193:283-292.
14. Lara D.R., Schmidt A.P., Frizzo M.E., Burgos J.S., Ramirez G., Souza D.O. Effect of orally administered guanosine on seizures and death induced by glutamatergic agents. Brain Res 2001, 912:176-180.
15. Lipton S.A., Rosenberg P.A. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994, 330:613-622.
16. Malcon C., Achaval M., Komlos F., Partata W., Sauressig M., Ramirez G., et al. GMP protects against quinolinic acid-induced loss of NADPH-diaphorase-positive cells in the rat striatum. Neurosci Lett 1997, 225:145-148.
17. Maragakis N.J., Rothstein J.D. Mechanisms of disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol 2006, 2:679-689.
18. Meldrum B.S. The role of glutamate in epilepsy and other CNS disorders. Neurology 1994, 44:14-23.
19. Mendieta J., Gago F., Ramirez G. Binding of 5'-GMP to the GluR2 AMPA receptor: insight from targeted molecular dynamics simulations. Biochemistry 2005, 44:14470-14476.
20. Nutt D.J., Malizia A.L. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry 2001, 179:390-396.
21. Ozawa S., Kamiya H., Tsuzuki K. Glutamate receptor in the mammalian central nervous system. Prog Neurobiol 1998, 54:581-618.
22. Paas Y., Thiery A.D., Changeux J.P., Medevielle F., Teichberg V.I. Identification of an extracellular motif involved in the binding of guanine nucleotides by a glutamate receptor. EMBO J 1996, 15:1548-1556.
23. Palucha A., Pilc A. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol Ther 2007, 115:116-147.
24. Paz M.M., Ramos M., Ramirez G., Souza D.O. Differential effects of guanine nucleotides on kainic acid binding and on adenylate cyclase activity in chick optic tectum. FEBS Lett 1994, 355:205-208.
25. Plaznik A., Palejko W., Nazar M., Jessa M. Effects of antagonists at the NMDA receptor complex in two models of anxiety. Eur Neuropsychopharmacol 1994, 4:503-512.
26. Pellow S., Chopin P., File S.E., Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J of Neurosci Methods 1986, 14:149-167.
27. Porciúncula L.O., Vinade L., Wofchuk S., Souza D.O. Guanine based purines inhibit [H] glutamate and [H]AMPA binding at postsynaptic densities from cerebral cortex of rats. Brain Res 2002, 928:106-112.
28. Prut L., Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 2003, 463:3-33.
29. Regner A., Ramírez G., Belló-Klein A., Souza D.O. Effects of guanine nucleotides on glutamate induced chemiluminescence in rat hippocampal slices submitted to hypoxia. Neurochem Res 1998, 23:519-524.
30. Roesler R., Vianna M.R., Lara D.R., Izquierdo I., Schmidt A.P., Souza D.O. Guanosine impairs inhibitory avoidance performance in rats. Neuroreport 2000, 11:2537-2540.
31. Rubin M.A., Jurach A., Costa E.M., Lima T.T., Jimenez-Bernal R.E., Begnini J., et al. GMP reverses the facilitatory effect of glutamate on inhibitory avoidance task in rats. NeuroReport 1996, 7:2078-2080.
32. Saute J.A., da Silveira L.E., Soares F.A., Martini L.H., Souza D.O., Ganzella M. Amnesic effect of GMP depends on its conversion to guanosine. Neurobiol Learn Mem 2006, 85:206-212.
33. Schmidt A.P., Lara D.R., Maraschin J.F., Perla A.S., Souza D.O. Guanosine and GMP prevent seizures induced by quinolinic acid in mice. Brain Res 2000, 864:40-43.
34. Schmidt A.P., Ávila T.T., Souza D.O. Intracerebroventricular guanine-based purines protect against seizures induced by quinolinic acid in mice. Neurochem Res 2005, 30:69-73.
35. Schmidt A.P., Lara D.R., Souza D.O. Proposal of a guanine-based purinergic system in the mammalian central nervous system. Pharmacol Ther 2007, 116:401-416.
36. Schmidt A.P., Böhmer A.E., Leke R., Schallenberger C., Antunes C., Pereira M.S., et al. Antinociceptive effects of intracerebroventricular administration of guanine-based purines in mice: evidences for the mechanism of action. Brain Res 2008, 1234:50-58.
37. Schmidt A.P., Böhmer A.E., Antunes C., Schallenberger C., Porciúncula L.O., Elisabetsky E., et al. Anti-nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1 adenosine receptors. Br J Pharmacol 2009, 156(1):163-172.
38. Segovia G., Porras A., Del Arco A., Mora F. Glutamatergic neurotransmission in aging: a critical perspective. Mech Ageing Dev 2001, 122(1):1-29.
39. Sheldon A.L., Robinson M.B. The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int 2007, 51:333-355.
40. Soares F.A., Schmidt A.P., Farina M., Frizzo M.E., Tavares R.G., Portela L.V. Anticonvulsant effect of GMP depends on its conversion to guanosine. Brain Res 2004, 1005:182-186.
41. Souza D.O., Ramirez G. Effects of guanine nucleotides on kainic acid binding and on adenylate cyclase in chick optic tectum and cerebellum. J Mol Neurosci 1991, 3:39-45.
42. Spooren W., Gasparini F. mGlu5 receptor antagonists: a novel class of anxiolytics?. Drug News Perspect 2004, 17:251-257.
43. Strazielle N., Ghersi-Egea J.F. Factors affecting delivery of antiviral drugs to the brain. Rev Med Virol 2005, 15(2):105-133.
44. Takeda M., Khamdang S., Narikawa S., Kimura H., Kobayashi Y., Yamamoto T., et al. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther 2002, 300:918-924.
45. Tasca C.I., Wofchuk S.T., Souza D.O., Ramirez G., Rodnight R. Guanine nucleotides inhibit the stimulation of GFAP phosphorylation by glutamate. NeuroReport 1995, 6:249-252.
46. Tatarczynska E., Klodzinska A., Chojnacka-Wojcik E., Palucha A., Gasparini F., Kuhn R. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 2001, 132:1423-1430.
47. Tatarczynska E., Klodzinska A., Kroczka B., Chojnacka-Wojcik E., Pilc A. The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration. Psychopharmacology 2001, 158:94-99.
48. Tort A.B., Mantese C.E., dos Anjos G.M., Dietrich M.O., Dall'Igna O.P. Guanosine selectively inhibits locomotor stimulation induced by the NMDA antagonist dizocilpine. Behav Brain Res 2004, 154:417-422.
49. Vinadé E.R., Schmidt A.P., Frizzo M.E., Izquierdo I., Elizabetsky E., Souza D.O. Chronically administered guanosine is anticonvulsant, amnesic and anxiolytic in mice. Brain Res 2003, 977:97-102.
50. Vinadé E.R., Schmidt A.P., Frizzo M.E., Portela L.V., Soares F.A., Schwalm F.D. Effects of chronic administered guanosine on behavioral parameters and brain glutamate uptake in rats. J Neurosci Res 2005, 79:248-253.